Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 351 to 375 of 872

TitleReference numberPublishedLast updated
Fremanezumab for preventing migraineTA764
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableTA765
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanomaTA766
Sodium zirconium cyclosilicate for treating hyperkalaemiaTA599
Cabotegravir with rilpivirine for treating HIV-1TA757
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsyTA758
Mogamulizumab for previously treated mycosis fungoides and Sézary syndromeTA754
Belimumab for treating active autoantibody-positive systemic lupus erythematosusTA752
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)TA750
Dupilumab for treating severe asthma with type 2 inflammationTA751
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disordersTA748
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)TA749
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancerTA746
Nintedanib for treating progressive fibrosing interstitial lung diseasesTA747
Upadacitinib for treating moderate rheumatoid arthritisTA744
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal)TA745
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancerTA740
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA741
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitableTA739
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapyTA736
Berotralstat for preventing recurrent attacks of hereditary angioedemaTA738
Tofacitinib for treating juvenile idiopathic arthritisTA735
Secukinumab for treating moderate to severe plaque psoriasis in children and young peopleTA734
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)TA732
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA733

Results per page

  1. 10
  2. 25
  3. 50
  4. All